Note 10 - Stock-Based Compensation

6 Months Ended

Jun. 30, 2015

Disclosure of Compensation Related Costs, Share-based Payments [Text Block]

10 .	Stock-Based Compensation

During the three and six months ended June 30, 2015, the Company granted options to purchase 6,650 shares of its common stock and no options were exercised. During the three and six months ended June 30, 2015, options to purchase an aggregate of 418,649 and 556,624 shares of common stock were cancelled or expired unexercised. Options to purchase an aggregate of 3,098,273 shares of common stock were outstanding as of June 30, 2015, and options to purchase an aggregate of 1,526,516 shares of common stock were exercisable as of June 30, 2015.

During the three months ended June 30, 2015, the Company amended certain options to extend the vesting and the post-termination exercise period, resulting in additional stock-based compensation expense of $45,953 in the three and six months ended June 30, 2015.

On March 5, 2015, the Company’s Board of Directors approved the RestorGenex Corporation 2015 Equity Incentive Plan (the “2015 Equity Plan”), and on June 17, 2015, the Company’s stockholders approved the 2015 Equity Plan. The 2015 Equity Plan allows for the issuance of up to a maximum of 2,500,000 shares of common stock in connection with the grant of stock-based awards, including stock options, restricted stock, restricted stock units, stock appreciation rights and other types of awards as deemed appropriate. As of June 30, 2015, options to purchase 6,650 shares of common stock were outstanding and 2,493,350 shares of common stock remained available for grant under the 2015 Equity Plan.

Options are granted with per share exercise prices equal to the per share fair value of the common stock on the date of grant. The Company recognizes the fair value of stock-based awards granted in exchange for employee and non-employee services as a cost of those services. The Company recognizes stock-based compensation expense for option awards on a straight-line basis over the vesting period.

The following table summarizes the stock-based compensation expense for employees and non-employees recognized in the Company’s condensed consolidated statements of operations for the periods indicated:

	Three Months Ended June 30 ,				Six Months Ended June 30 ,
	2015		2014		2015		2014
Research and development	$	152,645	$	32,825	$	384,170	$	32,825
General and administrative		374,544		108,490		748,446		258,375
Total stock-based compensation expense	$	527,189	$	141,315	$	1,132,616	$	291,200

As of June 30, 2015, the Company had $3,637,492 of total unrecognized compensation cost related to unvested stock-based compensation arrangements granted to employees. That cost is expected to be recognized over a weighted-average service period of 1.91 years.